In patients who then had an actual ( last ) dose of @mg during the extension blinded Conversion Period ( n = @ ) , median percent change in seizure frequency per @days improved from -@ % ( @mg , phase III Maintenance Period ) to -@ % ( @mg , extension blinded Conversion Period ) ; @ % responder rates increased slightly from @ % to @ % .